WednesdayMar 31, 2021 2:15 pm

Australian Government to Give $15M Grant for Psychedelics Research Focusing on Mental Health

The federal government of Australia will be granting $15 million to clinical studies that look into the use of psychedelics substances such as ecstasy and psilocybin mushrooms for the treatment of mental health conditions. This grant is an important breakthrough in the fight against mental illnesses, especially with nearly half of all adults in Australia set to face mental health issues in the course of their lives. Black Dog Institute, a medical research institute that is dedicated to studying mental health, found that one in five adults experience symptoms of mental conditions in any given year. In the country, that’s…

Continue Reading

TuesdayMar 30, 2021 1:30 pm

Tryp Therapeutics (CSE: TRYP) (OTC: TRYPF) Files Provisional Patent for New Psychedelic Delivery Methods

Last week, Tryp Therapeutics issued a statement announcing the submission of a provisional patent to enhance how psychedelics are dispensed across various indications. Tryp Therapeutics is a pharmaceutical company engaged in the development of compounds with known activity and safety profiles for the treatment of rare ailments that currently have no approved treatments. The company has a psilocybin program called the PFN(TM) program that works on developing synthetic psilocybin as a new therapy for specific neuropsychiatric disorders. The patent details new techniques for the development, dosing and delivery of psychedelics, which may help decrease the time a patient spends in…

Continue Reading

MondayMar 29, 2021 2:32 pm

Washington D.C. Psychedelics Decriminalization Measure Takes Effect

During the November 2020 elections, voters in Washington, DC, approved a ballot measure that would decriminalize fungi and plant-based entheogens. Last week, the measure came into effect, with a wide range of psychedelic substances such as ayahuasca and psilocybin officially becoming the lowest priority for local law enforcement. Despite this, activists from the Plant Medicine Coalition (“PMC”) who were behind the initiative are now calling for the enactment of additional laws to provide child and worker protections associated with the use of these fungi and plant-based substances. The activists are asking that the city provide guidelines to law enforcement about…

Continue Reading

MondayMar 29, 2021 11:54 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Orders First Functional Mushroom Shipment for Global E-Commerce Portal

PULL expands into EU through initial sale of cannabis oil extracts to German pharmaceutical company Sale to Germany expected to pave way for additional supply agreements throughout Europe Company orders first shipment of functional mushroom products for direct-to-consumer e-commerce portal, expects $15,000 gross monthly sales for each formulation PULL’s new state-of-the-art facility constructed to EU GMP standards for worldwide exports With a focus on the cannabis, hemp, functional mushrooms and rapidly emerging psychedelic sectors, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a Canadian plant-based extraction company, is steadily increasing its market share through the achievement of several important…

Continue Reading

FridayMar 26, 2021 12:13 pm

Educational App That Demonstrates Psychedelics Effects on the Brain Launches

Psychedelic drugs such as psilocybin mushrooms have been used for centuries in various cultures across the globe before becoming popular in the Western world in the 1960s. Recently, the substances, most of which are naturally occurring substances, have been utilized in research studies in various parts of the world, with the objective being to help develop treatments for various mental health conditions. For instance, a study conducted by researchers from Johns Hopkins Medicine found that two doses of psilocybin produced large and fast reduction in the depressive symptoms of study participants, with some achieving remission through a one month follow-up.…

Continue Reading

ThursdayMar 25, 2021 3:00 pm

Lifetime Use of Classic Psychedelics Could Decrease Risk of Hypertension

Research recently reported in “Hypertension” has found that lifetime use of classic psychedelics may be associated with a lower risk of hypertension. Otto Simonsson, from University of Oxford’s department of sociology, stated that the findings demonstrated that classic psychedelic use was linked to a 14% lower chance of hypertension, adding that lifetime use of tryptamine was linked to a 20% lower chance of hypertension. Simonsson and his colleagues noted that these results may be valuable in helping understand the physical health after effects of classic psychedelic use, with randomized controlled trials being conducted to look into the possible ways that…

Continue Reading

WednesdayMar 24, 2021 12:15 pm

Seattle Doctor Sues DEA over Psilocybin Mushroom Access for Terminally Ill Patients

A doctor from Seattle who hopes to broaden access to hallucinogenic mushrooms for terminally ill cancer patients is suing the U.S. Drug Enforcement Administration (“DEA”) over its recent denial of an application to legally utilize psilocybin mushrooms in end-of-life treatment. The doctor’s attorneys filed the lawsuit last week in the 9th Circuit’s U.S. Circuit Court of Appeals. They argued that the DEA denying the application was baseless. The attorneys are asking judges to dismiss the decision and force the DEA to reconsider and accommodate reasonable requests made from qualified health practitioners for the therapeutic use of psilocybin. On a press…

Continue Reading

TuesdayMar 23, 2021 2:45 pm

Scientists Find Ideal Psychedelic Dose for Use in Psychiatric Treatment

Research that was conducted recently to identify the effects of LSD has been reported in the “Neuropsychopharmacology” journal. The discoveries will be used to plan clinical trials that examine the use of LSD in patients with various psychiatric disorders. Prior research had discovered that LSD could be a treatment for some mental conditions when used in combination with psychotherapy. However, these studies compared LSD doses to placebo. Researchers for the new study focused on testing the effects of LSD in different doses. Matthias E. Liechti, a researcher from the University Hospital Basel, stated that the group or researchers wanted to…

Continue Reading

MondayMar 22, 2021 11:38 am

Pure Extracts Technologies Corp.’s (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Subsidiary Pure Mushrooms Corp. Submits Application to Health Canada for a Dealer’s License

Pure Extracts Technologies Corp.’s subsidiary Pure Mushrooms Corp. has submitted an application to Health Canada for a Dealer’s License Award of a Dealer’s License will enable company to procure controlled substances, conduct research, carry out business-to-business sales Pure Extracts has recently commenced a study into psilocybin-based active treatments, with research set to be carried out under auspices of Toronto Institute of Pharmaceutical Technology Functional mushroom, psychedelic drug market is forecast to grow to value of $6.85 billion by 2027 Pure Extracts Technologies (CSE: PULL) (XFRA: A2QJAJ) (XFRA: A2QJAJ), a plant-based extraction company focused on the cannabis, hemp, functional mushrooms and…

Continue Reading

MondayMar 22, 2021 10:15 am

Study Finds Users of Psychedelics Have Better Physical Health Than Non-Users

Recent research has found that using psychedelic substances has been linked to better physical health. However, the cause of the link between the two is still not clear. The study’s corresponding author, Otto Simonsson, stated that while a lot of research on classic psychedelics had shown the various mental health benefits they possessed, little was known about how these psychedelics may impact long-term physical health outcomes. Simonsson, who is from the University of Oxford, added that he was curious to find out. For purposes of their research, the researchers examined data collected from 171,766 individuals who responded to surveys conducted…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050